Varenicline and Nicotine Interactions in Humans (VA)

Completed 37 enrolled Yale University National Institute on Drug Abuse (NIDA) · collab US Department of Veterans Affairs · collab

RandomizedCrossoverDouble-blindTreatment

Summary

To examine the effects of varenicline on the subjective, physiological and cognitive responses to intravenous nicotine. Varenicline is a partial nicotine agonist and it is approved as a treatment for smoking cessation. We predict that varenicline treatment will modify subjective, physiological and cognitive responses to IV nicotine.

Timeline

Start: 2007-08
Primary completion: 2008-11
Completion: 2009-11

Publications

Results Sofuoglu M, Herman AI, Mooney M, Waters AJ. Varenicline attenuates some of the subjective and physiological effects of intravenous nicotine in humans. Psychopharmacology (Berl). 2009 Nov;207(1):153-62. doi: 10.1007/s00213-009-1643-z. Epub 2009 Aug 20.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Nicotine	Unknown	0.1 mg	Intravenous
Subject	Nicotine	Unknown	0.4 mg	Intravenous
Subject	Nicotine	Unknown	0.7 mg	Intravenous
Subject	Varenicline	Small molecule	1 mg	—

Indications

No indication recorded.